HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infirst’s Flarin Lipid Ibuprofen Trialled As COVID-19 Treatment

Executive Summary

A clinical trial will explore the effectiveness of OTC ibuprofen drug Flarin in reducing COVID-19 related respiratory failure in hospitalized patients, following "compelling" pre-clinical data.

You may also be interested in...

David Vs Goliath – Flarin’s Macmillen On Slugging It Out With The Heavyweights

HBW Insight Exclusive: Flarin boss Andrew Macmillen on competing with the big OTC incumbents as a lean, innovation-focused company.

Studies To Investigate If Betadine Mouthwash Can Prevent COVID-19 Infection

Clincal studies planned to test if povidone-iodine, marketed widely as consumer health products under the brand name Betadine, can prevent infection with the novel coronavirus.

Daring To Be 'Different' Lands Infirst In Hot Water

ASA tells Infirst that use of the word "different" in marketing implies its Flarin analgesic is more effective than other ibuprofen OTC drugs sold in the UK.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts